Oral Cladribine in Early Multiple Sclerosis (MS)

NCT00725985 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

617

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Cladribine
DRUG: Placebo
DRUG: Rebif® new formulation (RNF)

Sponsor

EMD Serono Research & Development Institute, Inc.